Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q1 2018 · 10-Q
Revenue$701.00K$701.00K+110.5% vs Q1 2017 Net Income-$63.55M-$63.55MN/M vs Q1 2017 EPS Diluted-$0.50-$0.50N/M vs Q1 2017 Gross Profit$592,000+77.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flow-$10,338,000N/M Free Cash Flowderived-$10,536,000N/M Margins · derivedGross margin84.5%−15.5 pt vs Q1 2017
Operating margin-1738.5%+1643.5 pt vs Q1 2017
Net margin-9065.3%
ended Mar 31, 2018 · filed May 10, 2018 · 40 d after period end